407 related articles for article (PubMed ID: 26409255)
21. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
Ma YL; Hamang M; Lucchesi J; Bivi N; Zeng Q; Adrian MD; Raines SE; Li J; Kuhstoss SA; Obungu V; Bryant HU; Krishnan V
Bone; 2017 Apr; 97():20-28. PubMed ID: 27939957
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
Li X; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Grisanti M; Dwyer D; Stouch B; Thway TM; Stolina M; Ominsky MS; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
J Bone Miner Res; 2010 Dec; 25(12):2647-56. PubMed ID: 20641040
[TBL] [Abstract][Full Text] [Related]
23. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats.
Feng G; Chang-Qing Z; Yi-Min C; Xiao-Lin L
Int Immunopharmacol; 2015 Jan; 24(1):7-13. PubMed ID: 25479724
[TBL] [Abstract][Full Text] [Related]
24. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model.
Virk MS; Alaee F; Tang H; Ominsky MS; Ke HZ; Lieberman JR
J Bone Joint Surg Am; 2013 Apr; 95(8):694-701. PubMed ID: 23595067
[TBL] [Abstract][Full Text] [Related]
25. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss.
Beggs LA; Ye F; Ghosh P; Beck DT; Conover CF; Balaez A; Miller JR; Phillips EG; Zheng N; Williams AA; Aguirre JI; Wronski TJ; Bose PK; Borst SE; Yarrow JF
J Bone Miner Res; 2015 Apr; 30(4):681-9. PubMed ID: 25359699
[TBL] [Abstract][Full Text] [Related]
26. Sclerostin Antibody Increases Callus Size and Strength but does not Improve Fracture Union in a Challenged Open Rat Fracture Model.
Morse A; McDonald MM; Schindeler A; Peacock L; Mikulec K; Cheng TL; Liu M; Ke HZ; Little DG
Calcif Tissue Int; 2017 Aug; 101(2):217-228. PubMed ID: 28391431
[TBL] [Abstract][Full Text] [Related]
27. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia.
Chandler H; Brooks DJ; Hattersley G; Bouxsein ML; Lanske B
Osteoporos Int; 2019 Aug; 30(8):1607-1616. PubMed ID: 31053927
[TBL] [Abstract][Full Text] [Related]
28. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
Tian X; Jee WS; Li X; Paszty C; Ke HZ
Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
[TBL] [Abstract][Full Text] [Related]
29. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
Liu Y; Rui Y; Cheng TY; Huang S; Xu L; Meng F; Lee WY; Zhang T; Li N; Li C; Ke H; Li G
Calcif Tissue Int; 2016 Mar; 98(3):263-74. PubMed ID: 26603303
[TBL] [Abstract][Full Text] [Related]
30. Sclerostin antibody stimulates bone regeneration after experimental periodontitis.
Taut AD; Jin Q; Chung JH; Galindo-Moreno P; Yi ES; Sugai JV; Ke HZ; Liu M; Giannobile WV
J Bone Miner Res; 2013 Nov; 28(11):2347-56. PubMed ID: 23712325
[TBL] [Abstract][Full Text] [Related]
31. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
Ominsky MS; Niu QT; Li C; Li X; Ke HZ
J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
[TBL] [Abstract][Full Text] [Related]
32. Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Kimoto A; Tanaka M; Nozaki K; Mori M; Fukushima S; Mori H; Shiroya T; Nakamura T
Bone; 2013 Jul; 55(1):189-97. PubMed ID: 23486179
[TBL] [Abstract][Full Text] [Related]
33. Sclerostin Antibody Reverses the Severe Sublesional Bone Loss in Rats After Chronic Spinal Cord Injury.
Zhao W; Li X; Peng Y; Qin Y; Pan J; Li J; Xu A; Ominsky MS; Cardozo C; Feng JQ; Ke HZ; Bauman WA; Qin W
Calcif Tissue Int; 2018 Oct; 103(4):443-454. PubMed ID: 29931461
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model.
Alaee F; Virk MS; Tang H; Sugiyama O; Adams DJ; Stolina M; Dwyer D; Ominsky MS; Ke HZ; Lieberman JR
J Orthop Res; 2014 Feb; 32(2):197-203. PubMed ID: 24600701
[TBL] [Abstract][Full Text] [Related]
35. Sclerostin antibody treatment improves implant fixation in a model of severe osteoporosis.
Virdi AS; Irish J; Sena K; Liu M; Ke HZ; McNulty MA; Sumner DR
J Bone Joint Surg Am; 2015 Jan; 97(2):133-40. PubMed ID: 25609440
[TBL] [Abstract][Full Text] [Related]
36. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
[TBL] [Abstract][Full Text] [Related]
37. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
38. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis.
Eddleston A; Marenzana M; Moore AR; Stephens P; Muzylak M; Marshall D; Robinson MK
J Bone Miner Res; 2009 Oct; 24(10):1662-71. PubMed ID: 19419292
[TBL] [Abstract][Full Text] [Related]
39. Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model?
Alzahrani MM; Rauch F; Hamdy RC
Clin Orthop Relat Res; 2016 May; 474(5):1294-302. PubMed ID: 26608966
[TBL] [Abstract][Full Text] [Related]
40. Qualitative alterations of cortical bone in female rats after long-term administration of growth hormone and glucocorticoid.
Ortoft G; Oxlund H
Bone; 1996 Jun; 18(6):581-90. PubMed ID: 8806000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]